Glucocorticoids in myocardial and cerebral infarction

M. Koltai, A. Tósaki, I. Leprán, L. Szekeres

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The results reported here indicate that under appropriate conditions glucocorticoids may induce a reproducible protective effect in experimental AMI and stroke in the rat and provide the first evidence that the DXM-induced protection may be mediated via the formation and release of lipocortins, thus being able to prevent AA release and generation of injurious mediators. Large scale production of lipocortins is required for further studies on their antiischemic and antiarrhythmic effect in various models and different species as well as for the elucidation of their mode of action. It seems likely that lipocortin release is an underlying mechanism in the organism against various damaging factors. The glucocorticoid controversy in prevention of ischemic disorders may at least in part be due to the fact that little attention has been paid to stress conditions in animal experiments. It is premature to predict whether lipocortins would be appropriate for human therapy. Some undesirable effects of steroid treatment, e.g. teratogenicity [77], might also be mediated via lipocortin release. Intracisternal administration of human lipocortin might be useful in cases of severe acute cerebral edema when the traumatized cells may be incapable of responding to glucocorticoid treatment.

Original languageEnglish
Pages (from-to)278-283
Number of pages6
JournalAgents and Actions
Volume17
Issue number3-4
DOIs
Publication statusPublished - Jan 1986

Fingerprint

Annexins
Cerebral Infarction
Glucocorticoids
Myocardial Infarction
Brain Edema
Rats
Animals
Stroke
Steroids

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology (medical)

Cite this

Glucocorticoids in myocardial and cerebral infarction. / Koltai, M.; Tósaki, A.; Leprán, I.; Szekeres, L.

In: Agents and Actions, Vol. 17, No. 3-4, 01.1986, p. 278-283.

Research output: Contribution to journalArticle

Koltai, M. ; Tósaki, A. ; Leprán, I. ; Szekeres, L. / Glucocorticoids in myocardial and cerebral infarction. In: Agents and Actions. 1986 ; Vol. 17, No. 3-4. pp. 278-283.
@article{780dc4672d744e15a07349dfc013e47d,
title = "Glucocorticoids in myocardial and cerebral infarction",
abstract = "The results reported here indicate that under appropriate conditions glucocorticoids may induce a reproducible protective effect in experimental AMI and stroke in the rat and provide the first evidence that the DXM-induced protection may be mediated via the formation and release of lipocortins, thus being able to prevent AA release and generation of injurious mediators. Large scale production of lipocortins is required for further studies on their antiischemic and antiarrhythmic effect in various models and different species as well as for the elucidation of their mode of action. It seems likely that lipocortin release is an underlying mechanism in the organism against various damaging factors. The glucocorticoid controversy in prevention of ischemic disorders may at least in part be due to the fact that little attention has been paid to stress conditions in animal experiments. It is premature to predict whether lipocortins would be appropriate for human therapy. Some undesirable effects of steroid treatment, e.g. teratogenicity [77], might also be mediated via lipocortin release. Intracisternal administration of human lipocortin might be useful in cases of severe acute cerebral edema when the traumatized cells may be incapable of responding to glucocorticoid treatment.",
author = "M. Koltai and A. T{\'o}saki and I. Lepr{\'a}n and L. Szekeres",
year = "1986",
month = "1",
doi = "10.1007/BF01982620",
language = "English",
volume = "17",
pages = "278--283",
journal = "Inflammation Research",
issn = "1023-3830",
publisher = "Birkhauser Verlag Basel",
number = "3-4",

}

TY - JOUR

T1 - Glucocorticoids in myocardial and cerebral infarction

AU - Koltai, M.

AU - Tósaki, A.

AU - Leprán, I.

AU - Szekeres, L.

PY - 1986/1

Y1 - 1986/1

N2 - The results reported here indicate that under appropriate conditions glucocorticoids may induce a reproducible protective effect in experimental AMI and stroke in the rat and provide the first evidence that the DXM-induced protection may be mediated via the formation and release of lipocortins, thus being able to prevent AA release and generation of injurious mediators. Large scale production of lipocortins is required for further studies on their antiischemic and antiarrhythmic effect in various models and different species as well as for the elucidation of their mode of action. It seems likely that lipocortin release is an underlying mechanism in the organism against various damaging factors. The glucocorticoid controversy in prevention of ischemic disorders may at least in part be due to the fact that little attention has been paid to stress conditions in animal experiments. It is premature to predict whether lipocortins would be appropriate for human therapy. Some undesirable effects of steroid treatment, e.g. teratogenicity [77], might also be mediated via lipocortin release. Intracisternal administration of human lipocortin might be useful in cases of severe acute cerebral edema when the traumatized cells may be incapable of responding to glucocorticoid treatment.

AB - The results reported here indicate that under appropriate conditions glucocorticoids may induce a reproducible protective effect in experimental AMI and stroke in the rat and provide the first evidence that the DXM-induced protection may be mediated via the formation and release of lipocortins, thus being able to prevent AA release and generation of injurious mediators. Large scale production of lipocortins is required for further studies on their antiischemic and antiarrhythmic effect in various models and different species as well as for the elucidation of their mode of action. It seems likely that lipocortin release is an underlying mechanism in the organism against various damaging factors. The glucocorticoid controversy in prevention of ischemic disorders may at least in part be due to the fact that little attention has been paid to stress conditions in animal experiments. It is premature to predict whether lipocortins would be appropriate for human therapy. Some undesirable effects of steroid treatment, e.g. teratogenicity [77], might also be mediated via lipocortin release. Intracisternal administration of human lipocortin might be useful in cases of severe acute cerebral edema when the traumatized cells may be incapable of responding to glucocorticoid treatment.

UR - http://www.scopus.com/inward/record.url?scp=0022622859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022622859&partnerID=8YFLogxK

U2 - 10.1007/BF01982620

DO - 10.1007/BF01982620

M3 - Article

C2 - 2938453

AN - SCOPUS:0022622859

VL - 17

SP - 278

EP - 283

JO - Inflammation Research

JF - Inflammation Research

SN - 1023-3830

IS - 3-4

ER -